CD4 and neoplasm: Administration of FIP-fve as adjuvant therapy along with HPV-16 E7 vaccine to tumor bearing mice resulted in increased production of HPV-16 E7-specific antibodies and increased expansion of HPV-16 E7-specific interferon (IFN)-γ-producing CD4+ and CD8+ T cells compared with HPV-16 E7 vaccine alone, resulting prolonged lifespan of the mice (Ding et al., 2009).